74 results
Page 3 of 4
8-K
EX-10.1
i9otnwjxkduzrmu
26 Apr 22
Departure of Directors or Certain Officers
6:51am
8-K
EX-2.1
ql12l ekug4c
26 Oct 21
EyeGate adds Bayon Therapeutics’ portfolio of vision-restoring small molecules to its development pipeline
7:00am
8-K/A
EX-99.1
ryi7bz4u9z8w
5 Mar 21
Financial Statements and Exhibits
4:15pm
8-K/A
EX-99.2
b1r25qdmn9k
5 Mar 21
Financial Statements and Exhibits
4:15pm
8-K
EX-10.1
a2ul6dxj1 vq53iqn
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-10.2
y1w0q7c
1 Feb 21
Departure of Directors or Certain Officers
6:55am
8-K
EX-2.1
g5bacs ynw8
21 Dec 20
EyeGate Pharma Announces Transformative Acquisition of Panoptes Pharma
6:55am
8-K
EX-99.1
0szqw lb3lo1by90
14 Sep 20
Regulation FD Disclosure
6:50am
8-K
EX-99.1
zehbb
1 Jun 20
Regulation FD Disclosure
6:55am
8-K
EX-99.1
s6iwdhrcvy0
31 Mar 20
EyeGate Pharma Announces Positive Topline Data in Follow-on Dry Eye Pilot Study
6:55am
8-K
EX-99.1
21ys88q860nf cq3
31 Dec 19
EyeGate Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:05pm
8-K
EX-99.1
p445shsn
17 Dec 19
EyeGate Pharma Receives $1.9 Million From Exercised Warrants
8:41am
8-K
EX-99.1
90tlta4b4jl 1o844r
2 Dec 19
EyeGate Pharma Announces Additional Positive Top-Line Data in PRK Pivotal Study
6:55am